Phase 3 Depression and Anxiety Trial, Recruiting NCT06775379 Sponsor: Xenon Pharmaceuticals Inc. Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 3 Depression and Anxiety Trial, Recruiting

NCT06775379
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 to 74 whose first episode of major depression began before the age of 50
  • People with a Body Mass Index (BMI) of 40 or below
  • People who currently meet the formal medical diagnosis criteria for major depressive disorder (MDD), confirmed through a structured psychiatric interview
  • People whose current depressive episode has lasted at least 6 weeks but no longer than 24 months

Who may not be able to join:

  • People whose primary mood disorder diagnosis is something other than MDD
  • People with a history of MDD with psychotic or catatonic features, MDD with mixed features, Bipolar I or II disorder, obsessive-compulsive disorder, schizophrenia, or other psychotic disorders
  • People currently diagnosed with seasonal depression, depression related to childbirth or menopause, post-traumatic stress disorder, antisocial or borderline personality disorder, panic disorder, agoraphobia, or ADHD that is treated with stimulant medication, was diagnosed during the current depressive episode, or has unstable symptoms (confirm with trial site)
  • People who have had a problem with alcohol or drug use (not including tobacco) in the past 12 months
  • People who have had an active plan or intent to end their life in the past 6 months, any suicidal behaviour in the past 2 years, or more than one suicide attempt after the age of 24
  • People who have deliberately harmed themselves (without suicidal intent) in the past 12 months
  • People who have taken antidepressants or certain other restricted medications, including benzodiazepines, within the past 2 weeks (or 4 weeks for the antidepressant fluoxetine), or within a specific medication clearance period — whichever is longer (confirm with trial site)
  • People whose depression did not respond to two or more antidepressant medications at appropriate doses and durations during the current depressive episode
  • People with other medical conditions that could interfere with the study (confirm with trial site)
  • People who are pregnant, breastfeeding, or planning to become pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-604-484-3300

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Xenon Pharmaceuticals Inc.
Registry
ClinicalTrials.gov
Start date
20 December 2024
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov